NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Evotec SE (EVO) Stock Analysis

Evotec SE (EVO) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

EVO

$1.86

−$0.04 (−2.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EVO with… →

EVO Key Statistics

As of Sep 4, 2026
Trading
Open
$1.86
Previous Close
$1.90
Day's Range
1.84–1.86
52-Week Range
1.80–4.27
Volume
121.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.26
Valuation
Market Cap
$661.02M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.42
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.64
Financials (FY)
Revenue (FY)
$788.37M−1.08%
Net Income (FY)
−$103.52M
Profit marginThe share of revenue left as profit after all costs and taxes.
−27.47%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
355.39M
1-Year Return
−44.81%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
55.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EVO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.61%
2025−25.96%
2024−64.54%
2023+44.99%
2022−65.94%
2021+29.45%
2020+42.78%
2019+29.05%
2018+24.08%
2017+106.17%
2016 (partial year)+66.88%

As of September 4, 2026.

EVO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$788.37M−$103.52M−13.1%
2024$796.97M−$196.08M−24.6%
2023$781.43M−$83.91M−10.7%
2022$751.45M−$175.66M−23.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$788.37M$114.22M−$55.82M−$103.52M−13.1%
2024$796.97M$114.88M−$78.92M−$196.08M−24.6%
2023$781.43M$175.05M−$26.63M−$83.91M−10.7%
2022$751.45M$174.07M$20.85M−$175.66M−23.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EVO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricEVODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.922.3060% below
Profit margin−27.47%−3.14%24.3 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Evotec SE (EVO) at $661.02M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 4,461.

EVO last closed at $1.86 on September 4, 2026. That is −$0.04 (−2.11%) against the previous close. Over the past 52 weeks the price has ranged from $1.80 to $4.27. The latest close sits 3.33% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $788.37M. Against the prior fiscal year total of $796.97M, that is a change of −1.08%. The same year closed with a net loss of $103.52M. The reported profit margin is −27.47%. That is 24.3 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.64.

Across the 4 fiscal years on file, revenue moves from $751.45M in 2022 to $788.37M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.42. The price-to-sales ratio is 0.92. On price-to-sales that is 59.87% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned −44.81%. Measured over 10 years, that is −2.97% a year compounded. The reported beta is 1.26. Daily returns over the trailing 10 years annualize to a volatility of 52.15%.

Growth & Income

The record shows no dividend for EVO.

Across the complete calendar years on file, 2017 returned +106.17% and 2022 returned −65.94%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the price is −39.61%.

Peer Comparison

Evotec SE (EVO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Evotec SE EVO $661.02M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Evotec SE has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Visit website →